NCT02266342

GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry

Evaluation on the Treatment of Diseases of the Thoracic Aorta With the Thoracic Endoprosthesis GORE® TAG®

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 154 (actual)
• Sponsor: W.L.Gore & Associates · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a French Registry mandated by the French National Health Authority assessing long-term (5-years) safety of the GORE® TAG® Thoracic Endoprosthesis treating diseases of the thoracic aorta.

Detailed description

Endovascular therapy to treat thoracic disease seems to provide a plausible benefit compared to surgery in terms of operative mortality and severe morbidity. The French National Health Authority (HAS) requires a 5-year follow-up as part of the renewal of reimbursement for these endoprostheses in order to collect long-term follow-up data under real-life conditions of use.

Conditions

• Aortic Aneurysm, Thoracic
• Descending Thoracic Aortic Dissection
• Aortic Diseases
• Aorta Thoracic; Traumatic Rupture
• Penetrating Ulcer

Interventions

Type	Name	Description
DEVICE	GORE® TAG® Thoracic Endoprostheses	Endovascular therapy to treat thoracic disease

Timeline

• Start date: 2014-10-01
• Primary completion: 2021-12-01
• Completion: 2022-04-01
• First posted: 2014-10-17
• Last updated: 2024-04-19
• Results posted: 2024-04-19

Locations

1 site across 1 country: France